ESSA Pharma Inc.
ESSA Pharma Inc. (EPIX): 2 pipeline candidates · ~78 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
77.6 months
D/E 0.01 · 0% dilution
N/A
2 candidates
N/A
N/A
A transparent, data-derived signal for ESSA Pharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$86.0M
Quarterly Burn
$4.2M
Runway
77.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| masofaniten | — |
| van hip fracture system | — |
Frequently asked questions
How many drug candidates are in ESSA Pharma Inc.'s pipeline?
ESSA Pharma Inc. (EPIX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ESSA Pharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ESSA Pharma Inc. has approximately 77.6 months of cash runway.
Who is the CEO of ESSA Pharma Inc.?
David R. Parkinson David is the chief executive officer of ESSA Pharma Inc. (EPIX).
Get the full picture on ESSA Pharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.